EUVIMEDEUVIMED entdecken
Open Access

Outcomes of Early Rhythm Control Therapy in Patients With Atrial Fibrillation and a High Comorbidity Burden in Large Real-World Cohorts

Jannis Dickow iD, Shinwan Kany iD, Victor Roth Cardoso iD, Patrick T Ellinor iD, Georgios V Gkoutos iD, Holly K Van Houten iD, Paulus Kirchhof iD, Andreas Metzner, Peter A Noseworthy iD, Xiaoxi Yao iD, Andreas Rillig iD

Circulation: Arrhythmia and Electrophysiology · 2023-05 · 16 (5)

DOI: 10.1161/circep.122.011585 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Circulation: Arrhythmia and Electrophysiology, 2023-05. Verfasst von Jannis Dickow und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, University Heart and Vascular Center Hamburg, University Hospital Hamburg Eppendorf (J.D., S.K., P.K., A.M., A.R.). Hauptthemen laut MEDLINE: Atrial Fibrillation, Stroke, Heart Failure. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, British Heart Foundation, Department of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

A recent subanalysis of the EAST-AFNET 4 (Early Treatment of Atrial Fibrillation for Stroke Prevention Trial) suggests a stronger benefit of early rhythm control (ERC) in patients with atrial fibrillation and a high comorbidity burden when compared to patients with a lower comorbidity burden.

Methods

We identified 109 739 patients with newly diagnosed atrial fibrillation in a large United States deidentified administrative claims database (OptumLabs) and 11 625 patients in the population-based UKB (UK Biobank). ERC was defined as atrial fibrillation ablation or antiarrhythmic drug therapy within the first year after atrial fibrillation diagnosis. Patients were classified as (1) ERC and high comorbidity burden (CHA 2 DS 2 -VASc score ≥4); (2) ERC and lower comorbidity burden (CHA 2 DS 2 -VASc score 2–3); (3) no ERC and high comorbidity burden; and (4) no ERC and lower comorbidity burden. Patients without an elevated comorbidity burden (CHA 2 DS 2 -VASc score 0–1) were excluded. Propensity score overlap weighting and cox proportional hazards regression were used to balance patients and compare groups for the primary composite outcome of all-cause mortality, stroke, or hospitalization with the diagnoses heart failure or myocardial infarction as well as for a primary composite safety outcome of death, stroke, and serious adverse events related to ERC.

Results

In both cohorts, ERC was associated with a reduced risk for the primary composite outcome in patients with a high comorbidity burden (OptumLabs: hazard ratio, 0.83 [95% CI 0.72–0.95]; P =0.006; UKB: hazard ratio, 0.77 [95% CI, 0.63–0.94]; P =0.009). In patients with a lower comorbidity burden, the difference in outcomes was not significant (OptumLabs: hazard ratio, 0.92 [95% CI, 0.54–1.57]; P =0.767; UKB: hazard ratio, 0.94 [95% CI, 0.83–1.06]; P =0.310). The comorbidity burden interacted with ERC in the UKB (interaction- P =0.027) but not in OptumLabs (interaction- P =0.720). ERC was not associated with an increased risk for the primary safety outcome.

Conclusions

ERC is safe and may be more favorable in a population-based sample of patients with high a comorbidity burden (CHA 2 DS 2 -VASc score ≥4).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationStrokeHeart FailureHumansUnited StatesRisk AssessmentComorbidityRisk Factors

Stichwörter der Autor:innen

atrial fibrillationcatheter ablationcomorbidityheart failurestroke

Autor:innen und Institutionen

  • Department of Cardiology, University Heart and Vascular Center Hamburg, University Hospital Hamburg Eppendorf (J.D., S.K., P.K., A.M., A.R.).
  • DZHK (German Center for Cardiovascular Research), Partner Site Hamburg/Kiel/Lübeck, Berlin, Germany (J.D., S.K., P.K., A.M., A.R.).
  • Cardiovascular Disease Initiative, The Broad Institute of MIT and Harvard, Cambridge, MA (S.K., P.T.E.).
  • Institute of Cardiovascular Sciences (V.R.C., G.V.G., P.K.), University of Birmingham, United Kingdom.
  • Health Data Research UK, Midlands Site, Birmingham, United Kingdom (V.R.C., G.V.G.).
  • Cardiovascular Research Center, Massachusetts General Hospital, Boston (P.T.E.).

ORCID-Profile: Jannis Dickow, Shinwan Kany, Victor Roth Cardoso, Patrick T Ellinor, Georgios V Gkoutos, Holly K Van Houten, Paulus Kirchhof, Peter A Noseworthy, Xiaoxi Yao, Andreas Rillig

Förderung

  • NHLBI NIH HHS
  • British Heart Foundation
  • Department of Health
  • FDA HHS
  • Medical Research Council
  • AHRQ HHS
  • NIA NIH HHS

Zitieren

APA

Dickow, J., Kany, S., Roth Cardoso, V., Ellinor, P. T., Gkoutos, G. V., Van Houten, H. K., Kirchhof, P., Metzner, A., Noseworthy, P. A., Yao, X., & Rillig, A. (2023). Outcomes of Early Rhythm Control Therapy in Patients With Atrial Fibrillation and a High Comorbidity Burden in Large Real-World Cohorts. Circulation: Arrhythmia and Electrophysiology, 16(5). https://doi.org/10.1161/circep.122.011585

Vancouver

Dickow J, Kany S, Roth Cardoso V, Ellinor PT, Gkoutos GV, Van Houten HK, et al. Outcomes of Early Rhythm Control Therapy in Patients With Atrial Fibrillation and a High Comorbidity Burden in Large Real-World Cohorts. Circulation: Arrhythmia and Electrophysiology. 2023;16(5). doi:10.1161/circep.122.011585

BibTeX
@article{Dickow2023,
  author = {Dickow, Jannis and Kany, Shinwan and Roth Cardoso, Victor and Ellinor, Patrick T and Gkoutos, Georgios V and Van Houten, Holly K and Kirchhof, Paulus and Metzner, Andreas and Noseworthy, Peter A and Yao, Xiaoxi and Rillig, Andreas},
  title = {Outcomes of Early Rhythm Control Therapy in Patients With Atrial Fibrillation and a High Comorbidity Burden in Large Real-World Cohorts},
  journal = {Circulation: Arrhythmia and Electrophysiology},
  year = {2023},
  volume = {16},
  number = {5},
  doi = {10.1161/circep.122.011585}
}
Kostenlos starten →